News Grower

Independent coverage of AI, startups, and technology.

Ars Technica Apr 24, 2026 at 21:11 Big Tech Rising Hot

Europe—not US—first to authorize Moderna's combo mRNA flu-COVID vaccine

Amid RFK Jr.'s anti-vaccine agenda, Moderna withdrew its FDA application last year.

Signal weather

Rising

Momentum is building quickly, so this card is a good early entry point into the topic.

By Beth Mole Original source
Europe—not US—first to authorize Moderna's combo mRNA flu-COVID vaccine

Moderna's mRNA-based combination vaccine against both flu and COVID-19 has gotten the green light in Europe—but it continues to be shelved in the US, where it was developed. This week, the European Commission authorized Moderna to market the vaccine, mRNA-1083 or mCOMBRIAX, making it the world's first authorized combination shot for the two respiratory viruses. The decision follows a positive review in February from a key European Medicines Agency's committee, which paved the way for the approval. Moderna CEO Stéphane Bancel welcomed the news. "By combining protection against two significant respiratory viruses in a single dose, our vaccine aims to simplify immunization for adults, particularly those at high risk," Bancel said in a press release. "mCOMBRIAX offers an important new option for Europeans, while also aiming to strengthen the resilience of healthcare systems across Europe."Read full article Comments

Stay on the signal

Follow Europe—not US—first to authorize Moderna's combo mRNA flu-COVID vaccine

Follow this story beyond a single article: new follow-ups, adjacent sources, and the evolving storyline.

We send a confirmation link first, then only meaningful digests.

Story map

Understand this topic fast

A quick entry into the story: why it matters now, who is involved, and where to go next for context.

Why it matters now

Fresh coverage with immediate momentum.
There are already 6 connected articles in the same storyline to continue from here.
The story keeps orbiting around Amid RFK Jr, Anti Vaccine, and Anti Vaccine Agenda, so the entity pages are the fastest way to build context.
Ars Technica already has 4 follow-up stories on the same theme.

Topic constellation

Open the live map for this story

See which entities, story threads, sources, and follow-up articles shape this story right now.

Click nodes to continue

Entity Cluster Article Hub Source

Story timeline

Continue with this story

A short sequence of events and follow-up stories to understand the arc quickly.

Apr 24, 2026 at 22:05 Ars Technica

Google will invest as much as $40 billion in Anthropic

This follows a similar, but smaller, investment by Amazon just days ago.

Apr 24, 2026 at 21:11 Ars Technica

Europe—not US—first to authorize Moderna's combo mRNA flu-COVID vaccine

Amid RFK Jr.'s anti-vaccine agenda, Moderna withdrew its FDA application last year.

Apr 24, 2026 at 19:30 Ars Technica

FCC: Router ban includes portable hotspots, but not phones with hotspot features

FCC defines consumer routers expansively, updates FAQ to include Wi-Fi hotspots.

Apr 24, 2026 at 19:00 Ars Technica

Why are top university websites serving porn? It comes down to shoddy housekeeping.

Hundreds of subdomains from dozens of universities have been hijacked by scammers.

Apr 24, 2026 at 18:44 Ars Technica

In rare chickenpox case, itchy blisters mushroom into large, rubbery nodules

Treatment options are tricky. The teen opted to live with the masses.

Apr 24, 2026 at 17:41 Ars Technica

Soldier won $410K in Polymarket bets on timing of Maduro capture, US alleges

It's like "Pete Rose betting on his own team," Trump says of arrested soldier.

How reliable this looks

Signal and trust for Ars Technica

This source works at a rapid pace: 100% of recent stories land in the hot window, and 0% carry visible search signal.

Trusted

Reliability

92

Freshness

100

Sources in storyline

1

Related articles

More stories that share tags, source, or category context.

More from Ars Technica

Fresh reporting and follow-up coverage from the same newsroom.

Open source page